TY - JOUR
T1 - Citron Rho-interacting kinase mediates arsenite-induced decrease in endothelial nitric oxide synthase activity by increasing phosphorylation at threonine 497
T2 - Mechanism underlying arsenite-induced vascular dysfunction
AU - Seo, Jungwon
AU - Cho, Du Hyong
AU - Lee, Hyeon Ju
AU - Sung, Min Sun
AU - Lee, Jee Young
AU - Won, Kyung Jong
AU - Park, Jung Hyun
AU - Jo, Inho
N1 - Publisher Copyright:
© 2015 Elsevier Inc. All rights reserved.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - We reported that arsenite causes an acute decrease in nitric oxide (NO) production by increasing phosphorylation of endothelial NO synthase at threonine 497 (eNOS-Thr497); however, the detailed mechanism has not yet been clarified. Here, we investigated the kinase involving in arsenite-stimulated eNOS-Thr497 phosphorylation. Although treatment with H-89, a known protein kinase A (PKA) inhibitor, inhibited arsenite-stimulated eNOS-Thr497 phosphorylation, no inhibition was found in cells treated with other PKA inhibitors, including Rp-8-Br-cAMPS or PKI. Based on previous reports, we also tested whether RhoA mediates arsenite-stimulated eNOS-Thr497 phosphorylation and found that arsenite causes an acute increase in RhoA activity. Ectopic expression of dominant negative (DN)-RhoA significantly reversed arsenite-stimulated eNOS-Thr497 phosphorylation. An in vitro phosphorylation assay also revealed that the well-known Rho effectors, Rho-associated protein kinase 1/2 (ROCK1/2), directly phosphorylate eNOS-Thr497. Y27632, a selective ROCK inhibitor, reversed arsenite-stimulated eNOS-Thr497 phosphorylation. However, overexpression of a small interfering RNA (siRNA) against ROCK1/2 or DN-ROCK did not reverse arsenite-stimulated eNOS-Thr497 phosphorylation, thereby providing no conclusive evidence of a role for ROCK1/2. Knockdown of PKC-related protein kinase 1/2, another Rho effector, also did not reverse arsenite-stimulated eNOS-Thr497 phosphorylation. In contrast, we found that transfection with an siRNA against citron Rho-interacting kinase (CRIK), the other downstream effector of Rho, significantly reversed the arsenite-induced eNOS-Thr497 phosphorylation that was accompanied by restoration of eNOS enzymatic activity repressed by arsenite. Moreover, CRIK directly phosphorylated eNOS-Thr497 in vitro. Finally, we also found that arsenite increased eNOS-Thr497 phosphorylation and decreased acetylcholine-induced vessel relaxation in rat aortas. In conclusion, we demonstrate that arsenite acutely inhibits eNOS enzymatic activity and vessel relaxation in part by increasing the RhoA/CRIK/eNOS-Thr497 phosphorylation signaling axis, which provides a molecular mechanism underlying arsenite-induced impaired vascular diseases.
AB - We reported that arsenite causes an acute decrease in nitric oxide (NO) production by increasing phosphorylation of endothelial NO synthase at threonine 497 (eNOS-Thr497); however, the detailed mechanism has not yet been clarified. Here, we investigated the kinase involving in arsenite-stimulated eNOS-Thr497 phosphorylation. Although treatment with H-89, a known protein kinase A (PKA) inhibitor, inhibited arsenite-stimulated eNOS-Thr497 phosphorylation, no inhibition was found in cells treated with other PKA inhibitors, including Rp-8-Br-cAMPS or PKI. Based on previous reports, we also tested whether RhoA mediates arsenite-stimulated eNOS-Thr497 phosphorylation and found that arsenite causes an acute increase in RhoA activity. Ectopic expression of dominant negative (DN)-RhoA significantly reversed arsenite-stimulated eNOS-Thr497 phosphorylation. An in vitro phosphorylation assay also revealed that the well-known Rho effectors, Rho-associated protein kinase 1/2 (ROCK1/2), directly phosphorylate eNOS-Thr497. Y27632, a selective ROCK inhibitor, reversed arsenite-stimulated eNOS-Thr497 phosphorylation. However, overexpression of a small interfering RNA (siRNA) against ROCK1/2 or DN-ROCK did not reverse arsenite-stimulated eNOS-Thr497 phosphorylation, thereby providing no conclusive evidence of a role for ROCK1/2. Knockdown of PKC-related protein kinase 1/2, another Rho effector, also did not reverse arsenite-stimulated eNOS-Thr497 phosphorylation. In contrast, we found that transfection with an siRNA against citron Rho-interacting kinase (CRIK), the other downstream effector of Rho, significantly reversed the arsenite-induced eNOS-Thr497 phosphorylation that was accompanied by restoration of eNOS enzymatic activity repressed by arsenite. Moreover, CRIK directly phosphorylated eNOS-Thr497 in vitro. Finally, we also found that arsenite increased eNOS-Thr497 phosphorylation and decreased acetylcholine-induced vessel relaxation in rat aortas. In conclusion, we demonstrate that arsenite acutely inhibits eNOS enzymatic activity and vessel relaxation in part by increasing the RhoA/CRIK/eNOS-Thr497 phosphorylation signaling axis, which provides a molecular mechanism underlying arsenite-induced impaired vascular diseases.
KW - Arsenite
KW - Citron Rho-interactingkinase
KW - Endothelial nitricoxidesynthase
KW - Ex vivo vessel relaxation
KW - Nitric oxide
KW - Phosphorylation
KW - Rho
KW - Vascular disease
UR - http://www.scopus.com/inward/record.url?scp=84948461563&partnerID=8YFLogxK
U2 - 10.1016/j.freeradbiomed.2015.11.020
DO - 10.1016/j.freeradbiomed.2015.11.020
M3 - Article
C2 - 26593676
AN - SCOPUS:84948461563
SN - 0891-5849
VL - 90
SP - 133
EP - 144
JO - Free Radical Biology and Medicine
JF - Free Radical Biology and Medicine
ER -